Zolpidem vs. Emerging Hypnotics: Neuropsychiatric Effects and Ethical Considerations

Zolpidem is a widely used non-benzodiazepine hypnotic that is used as a treatment for insomnia due to its rapid onset and perceived safety. Nevertheless, rising clinical reports and post-marketing surveillance have identified serious neuropsychiatric adverse effects, such as hallucinations, perceptual disturbances, and complex sleep-related behaviors, such as sleep-driving and sleep-eating, as being frequent and often unnoticed by the patient. The consequences of such events can be severe personal injury and litigation. Regardless of these issues, there are few comparative data between zolpidem and newer hypnotics.

A narrative literature review was conducted using PubMed/MEDLINE, Scopus, and Web of Science for studies published between 2020 and 2025.

Zolpidem was commonly linked to complex sleep acts, amnesia, and hallucinations, especially when in high dosage and when the patients had psychiatric comorbidities. On the contrary, some more recent ones, like orexin receptor antagonists, were less subject to such adverse effects, whereas the melatonin-based therapies were associated with positive safety profiles but lesser hypnotic efficacy. A number of case reports reported criminal charges in relation to zolpidem-induced altered states of consciousness.

Zolpidem, despite its usefulness in the management of insomnia, has a relatively high likelihood of neuropsychiatric adverse effects, particularly among women, the elderly, psychiatric patients, and those who have undergone polypharmacy. Environmental risk-benefit evaluation must be performed cautiously and individually, prescribing zolpidem while taking into account patientspecific clinical and pharmacokinetic parameters.